Demographic and clinical characteristics and outcomes of stroke survivors who received treatment stratified by discharge disposition
| Variable | Overall n=280 | Home n=122 (43.6%) | IRF n=116 (41.4%) | SNF n=42 (15.0%) | P value |
| Age | 0.003 | ||||
| <65 | 97 (34.6%) | 50 (41.0%) | 42 (36.2%) | 5 (11.9%) | |
| ≥65 | 183 (65.4%) | 72 (59.0%) | 74 (63.8%) | 37 (88.1%) | |
| Sex | <0.001 | ||||
| Female | 132 (47.1%) | 65 (53.2%) | 40 (34.5%) | 27 (64.3%) | |
| Male | 148 (52.9%) | 57 (46.7%) | 76 (65.5%) | 15 (35.7%) | |
| Race | 0.885 | ||||
| Black | 51 (18.2%) | 21 (17.2%) | 20 (17.2%) | 10 (23.8%) | |
| Other | 59 (21.1%) | 26 (21.3%) | 24 (20.7%) | 9 (21.4%) | |
| White | 170 (60.7%) | 75 (61.5%) | 72 (62.1%) | 23 (54.8%) | |
| NIHSS on Admission | <0.001 | ||||
| 0–9 | 120 (42.9%) | 82 (67.2%) | 30 (25.9%) | 8 (19.0%) | |
| 10–19 | 103 (36.8%) | 26 (21.3%) | 56 (48.3%) | 21 (50.0%) | |
| 20–42 | 56 (20.0%) | 14 (11.5%) | 29 (25.0%) | 13 (31.0%) | |
| Missing | 1 (0.4%) | 0 (0.0%) | 1 (0.9%) | 0 (0.0%) | |
| Stroke risk factors | |||||
| Atrial fibrillation | 59 (21.1%) | 20 (15.6%) | 22 (19.0%) | 18 (42.9%) | <0.001 |
| Coronary artery disease | 46 (16.4%) | 20 (16.4%) | 15 (12.9%) | 11 (26.2%) | 0.138 |
| Diabetes mellitus | 54 (19.3%) | 23 (18.9%) | 20 (17.2%) | 11 (26.2%) | 0.447 |
| Dyslipidaemia | 105 (37.5%) | 48 (39.3%) | 36 (31.0%) | 21 (50.0%) | 0.080 |
| Hypertension | 171 (61.1%) | 67 (54.9%) | 75 (64.7%) | 29 (69.0%) | 0.158 |
| Obesity | 124 (44.3%) | 55 (45.1%) | 56 (48.3%) | 13 (31.0%) | 0.149 |
| Previous stroke | 25 (8.9%) | 10 (8.2%) | 7 (6.0%) | 8 (19.0%) | 0.038 |
| Smoker | 41 (14.6%) | 21 (17.2%) | 19 (16.4%) | 1 (2.4%) | 0.050 |
| Last known well time to arrival | 0.023 | ||||
| 0–6 hours | 248 (88.6%) | 111 (91.0%) | 105 (90.5%) | 32 (76.2%) | |
| 6–24 hours | 27 (9.6%) | 10 (8.2%) | 10 (8.6%) | 7 (16.7%) | |
| Missing | 5 (1.8%) | 1 (0.8%) | 1 (0.9%) | 3 (7.1%) | |
| Transfer | 0.007 | ||||
| Transfer | 137 (48.9%) | 49 (40.2%) | 70 (60.3%) | 18 (42.9%) | |
| Not transfer | 117 (41.8%) | 64 (52.5%) | 35 (30.2%) | 18 (42.9%) | |
| Missing | 26 (9.3%) | 9 (7.4%) | 11 (9.5%) | 6 (14.3%) | |
| IV-tPA | 233 (83.2%) | 112 (91.8%) | 89 (76.7%) | 32 (76.2%) | 0.003 |
| EVT | 111 (39.6%) | 26 (21.3%) | 66 (56.9%) | 19 (45.2%) | <0.001 |
| LOS | <0.001 | ||||
| ≤7 days | 160 (57.1%) | 111 (91.0%) | 39 (33.6%) | 10 (23.8%) | |
| >7 days | 120 (42.9%) | 11 (9.0%) | 77 (66.4%) | 32 (76.2%) | |
| Discharge mRS | <0.001 | ||||
| 0 | 64 (22.9%) | 55 (45.1%) | 6 (5.2%) | 3 (7.1%) | |
| 1 | 57 (20.4%) | 39 (32.0%) | 15 (12.9%) | 3 (7.1%) | |
| 2 | 36 (12.9%) | 18 (14.8%) | 16 (13.8%) | 2 (4.8%) | |
| 3 | 47 (16.8%) | 7 (5.7%) | 30 (25.9%) | 10 (23.8%) | |
| 4 | 61 (21.8%) | 1 (0.8%) | 41 (35.3%) | 19 (45.2%) | |
| 5 | 15 (5.4%) | 2 (1.6%) | 8 (6.9%) | 5 (11.9%) | |
| 30-day mRS | <0.001 | ||||
| 0 | 64 (22.9%) | 55 (45.1%) | 6 (5.1%) | 3 (7.1%) | |
| 1 | 57 (20.4%) | 39 (32.0%) | 15 (12.9%) | 3 (7.1%) | |
| 2 | 36 (12.9%) | 18 (14.8%) | 16 (13.8%) | 2 (4.8%) | |
| 3 | 46 (16.4%) | 7 (5.7%) | 30 (25.9%) | 9 (21.4%) | |
| 4 | 58 (20.7%) | 1 (0.8%) | 41 (35.3%) | 16 (38.1%) | |
| 5 | 15 (5.4%) | 2 (1.6%) | 8 (6.9%) | 5 (11.9%) | |
| 6 | 4 (1.4%) | 0 (0.0%) | 0 (0.0%) | 4 (9.5%) | |
| 90-day mRS | <0.001 | ||||
| 0 | 75 (26.8%) | 61 (50.0%) | 11 (9.5%) | 3 (7.1%) | |
| 1 | 59 (21.1%) | 38 (31.1%) | 19 (16.4%) | 2 (4.8%) | |
| 2 | 17 (6.1%) | 1 (0.8%) | 16 (13.8%) | 0 (0.0%) | |
| 3 | 46 (16.4%) | 15 (12.3%) | 26 (22.4%) | 5 (11.9%) | |
| 4 | 42 (15.0%) | 6 (4.9%) | 28 (24.1%) | 8 (19.0%) | |
| 5 | 19 (6.8%) | 0 (0.0%) | 12 (10.3%) | 7 (16.7%) | |
| 6 | 22 (7.9%) | 1 (0.8%) | 4 (3.4%) | 17 (40.5%) |
All variables were presented with n (%). The denominator for the stratified groups in the header is n=280. Comparison of the discharge groups were conducted using Pearson’s χ2 test.
EVT, endovascular therapy; IRF, inpatient rehabilitation facility; IV-tPA, intravenous tissue-type plasminogen activator; LOS, length of stay; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SNF, skilled nursing facility.